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Abstract Human immunodeficiency virus type 1 (HIV-1) Rev is 
a small RNA-binding protein which is essential for viral 
replication. To investigate the structure of Rev we have mapped 
the binding sites of a panel of monoclonal antibodies (mAb) by 
protein footprinting and identified a mAb protecting amino acids 
within both the N- and C-terminal parts of Rev. Our mapping 
results support a previously proposed structure (Auer et al., 
Biochemistry, 33 (1994) 2988-2996) predicting that a helix-
loop-helix motif in Rev brings the termini of the protein into 
proximity. Furthermore, we demonstrate that the binding sites 
mapped by protein footprinting are in agreement with conven-
tional epitope mapping results and that this technique provides an 
advantageous strategy for mapping discontinuous sites. 
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1. Introduction 
Human immunodeficiency virus type 1 (HIV-1) encodes a 
regulatory protein Rev which is required for expression of 
viral structural proteins. It binds to an RNA element, the 
Rev response element (RRE), and up-regulates the cytoplas-
mic appearance of incompletely spliced viral transcripts, 
thereby inducing a shift in viral protein synthesis from regu-
latory to structural proteins. Rev is 116 amino acids (aa) long 
and based on mutational analysis; it has been divided into 
functional domains essential for biological activity (Fig. 1A). 
These include an arginine-rich RNA-binding/nuclear localiza-
tion domain (aa 34-50) [1-4] encompassed by less well-defined 
sequences necessary for multimerization of the Rev protein 
[2,5-7], and a leucine-rich nuclear export signal (NES, aa 
78-83) [8,9]. Whereas the functional implications of the inter-
action between the cellular protein p32 and the RNA-binding 
domain remain unclear [10,11], the transport is probably 
mediated by one or multiple cellular protein(s) interacting 
with the NES. Thus far two types of factors have been de-
scribed: the nucleoporin-like protein Rab/hRip/Riplp [12-14] 
and the eukaryotic initiation factor 5A (eIF-5A) [15]. 
Determination of the 3-dimensional structure of full-length 
Rev by NMR and X-ray crystallography has been impeded by 
the strong tendency of the protein to aggregate at higher 
concentrations [16] and so far NMR has only solved the struc-
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ture of a peptide spanning the RNA-binding domain of Rev 
[17]. The information available on the full-length Rev struc-
ture derives mainly from circular dichroism (CD) experiments 
[18-22] and from a footprinting assay involving partial pro-
teolysis of the protein [23]. CD spectra have estimated that 
full-length Rev protein contains approximately 50% a-helix, 
and an analysis of fragments of Rev suggests that the majority 
of the N-terminal part of the protein (aa 8-66) is a-helical in 
solution, whereas the C-terminal part of the protein is struc-
turally more flexible [18]. A peptide spanning the RNA-bind-
ing domain of Rev (aa 34-50) also confines to an a-helical 
conformation [24], a feature recently confirmed by NMR [17]. 
Furthermore, partial proteolysis studies suggest that the 
RNA-binding domain is also a-helical in the context of the 
full-length protein [23]. A model suggested by Auer et al. 
implies, that the N-terminal a-helical is interrupted by a pro-
line-rich loop (aa 27-31) and that the flanking a-helical seg-
ments interact through conserved hydrophobic residues form-
ing a helix-loop-helix motif in Rev [18,25]. 
Using a protein footprinting approach, which involves lim-
ited proteolysis of N- or C-terminally radiolabeled Rev pro-
tein in either the free state or bound to a panel of monoclonal 
antibodies (mAb), we here report a different line of experi-
mental evidence supporting such a structure. 
2. Materials and methods 
2.1. Protein expression vectors 
The pGEX-GTH-Rev expression vector, producing C-terminally 
radiolabeled GST-tagged Rev protein, have been described previously 
[26]. In order to make Rev protein, containing His-tag and HMK site 
at opposite ends, two parent vectors were constructed. pET-His-H 
was obtained by annealing the two synthetic oligonucleotides 5'-
Table 1 
Comparison of Rev epitopes mapped by either peptide interaction 
analysis or protein footprinting 
mAb Peptide interaction* Prot. footprinting1' 
4G9 - c aa 5-15 
8E7, 9G2 aa 70- 84 aa 65- 85 
aa 75- 88 
1G7 aa 91-105 aa 95-105 
aa 96-110 
1G10 aa 91-105 aa 10- 20 
aa 96-110 aa 95-105 
"Eptope-mapping results from peptide interaction studies (see Section 
2). Rev peptides interacting with the indicated mAbs are numbered 
according to the Rev sequence. 
bAreas in Rev protected from proteolytic cleavage by indicated mAbs. 
Endoproteinases used: bromelain and proteinase K (Figs. 2 and 3), 
and Asp-N, trypsin, Glu-C, elastase and chymotrypsin (data not 
shown), n.d., not detected. 
cNo peptides were found to bind 4G9. 
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Fig. 1. Schematic representation of functional domains in the Rev fusion constructs used in this study. See text for details. C-terminally 32P-la-
beled Rev with either a GST (A), or a 6xHis (B) purification tag positioned at the N-terminus, and N-terminally 32P-labeled Rev with a C-ter-
minal 6XHis tag (C). NES, nuclear export signal; HMK, heart muscle kinase phosphorylation site. 
CATGCATCACCATCACCATCACGGATCCCCGGGAATTCGT-
CGTGCATCTGTTTGA and 5'-GATCTCAAACAGATGCACGA-
CGAATTCCCGGGGATCCTGGATGGTGATGGTGATG, and in-
serting the double-stranded fragment into a Ncol+BamHI digest of 
pETlldAEcoRI [26]. pET-H-His was created likewise from the oli-
gonucleotides: 5'-CATGCGTCGTGCATCTGTTGGATCCCCGG-
GAATTCATCACCATCACCATCACTGA and 5'-GATCTCAGTG-
ATGGTGATGGTGATGAATTCCCGGGGATCCAACAGATGC-
ACGACG. To obtain pET-His-Rev-H and pET-H-Rev-His a Bcli-
EcoRl cleaved Rev PCR fragment was generated as described previ-
ously [26] and inserted into the BamHl and EcoRl sites of pET-His-
H and pET-H-His, respectively. 
2.2. Production of radiolabeled proteins 
GST-tagged Rev protein was expressed from pGEX-GTH-Rev and 
radiolabeled as described [26]. To obtain His-tagged radiolabeled Rev 
proteins, pET-His-Rev-H and pET-H-Rev-His were expressed in E. 
coli strain BL21(DE3), containing an isopropyl-P-D-thiogalactopyra-
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Fig. 2. Autoradiograms of the mAb protection mapping of GST-Rev protein using bromelain. The Rev specific mAbs used were: (A) 9G2, 
1G7, 4G9, 4F2; and (B) 8E7 and 1G10 as indicated above the lanes. Horizontal arrows to the right indicate the position of the footprints pro-
duced by the denoted mAbs as compared to the control. Where just a single aa in the Rev sequence is given, the exact position of the cleavage 
site is known. C and T denote control lanes with un- and thrombin-digested GST-Rev, respectively. The thrombin cleavage site in Rev has pre-
viously been mapped to aa66 [23]. Only the portion of the gels covering Rev sequences is shown. 
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Fig. 3. mAb protection mapping of His-tagged Rev. Autoradiograms of proteinase K digested His-Rev (A), or Rev-His (B) proteins incubated 
with Tat mAb 4B4 (lanes 3 and 6) or Rev mAbs 9G2 (lanes 4 and 7) and 1G10 (lanes 5 and 8). Nomenclature is as in Fig. 2. As mentioned 
in the text the 9G2 protected bands migrate abnormally in (A). The exact reason for this discrepancy is not known but small C-terminally pep-
tide fragments created by certain endoproteinases (e.g. Asp-N and proteinase K) has previously been noted to migrate somewhat slower in 
polyacrylamide gels compared to fragments of the same theoretical size created by other endoproteinases [10,23]. 
noside inducible T7 RNA polymerase gene [27]. Proteins were purified 
under denaturing conditions and renatured as described previously 
[10]. Dialysed renatured protein was radiolabeled in solution with 
the HMK enzyme as described [26] and re-incubated with 20 ul of 
Ni2+-agarose to facilitate 5 washing steps in 500 ul of washing buffer 
(20 mM HEPES, pH 7.9, 200 mM NaCl, 20% glycerol and 10 mM p-
mercaptoethanol) to remove the HMK enzyme and unincorporated 
nucleotides. Radiolabeled protein was eluted from the Ni2+-agarose in 
100 ill of Rev elution buffer (500 mM NaCl, 200 mM imidazole, 50 
mM HEPES/KOH, pH 6.0). 
2.3. Monoclonal antibodies 
mAb 4B4 and mAbs 4G9, 4F2, 9G2, 8E7, 1G7, 1G10 were pro-
duced by immunising mice with E. coli produced wild-type Tat and 
Rev protein, respectively. mAbs were purified using mAbTrapG 
(Pharmacia). Epitope mapping, by binding experiments using over-
lapping peptides derived from the Rev sequence, has previously 
been done [28], and the results are summarized in Table 1. mAb 
4B4 binds to a fragment of the Tat protein comprising aa 49-86 [29]. 
2.4. Protein footprinting experiments 
All protein footprinting experiments were done as described previ-
ously [23] except only 1 ng of both GST- and His-tagged Rev were 
used. Proteinase concentrations in the final reaction mixtures were: 
bromelain, 5 pg/ul (1X) and 15 pg/ul (3x) for GST-Rev experiments 
and 50 pg/ul for His-Rev and Rev-His experiments; proteinase K 0.8 
pg/ul (IX) and 4 pg/jxl (5X). Elastase and chymotrypsin concentra-
tions were 10-30 pg/ul, and Asp-N, thrombin, trypsin and Glu-C were 
used as described [23]. 
3. Results and discussion 
3.1. Protein footprinting radiolabeled Rev with mAbs 
The topography of Rev was probed by mapping the binding 
sites of various Rev-specific mAbs using protein footprinting 
technology. To ease the amino acid identification, the protein 
had subsequently been 32P-labeled with the heart muscle kin-
ase enzyme (HMK) at the C-terminal HMK site (Fig. 1A). 
Assembled GST-Rev/mAb complexes were partially cleaved 
with the following proteinases: Asp-N, trypsin, Glu-C, elas-
tase, chymotrypsin, proteinase K (data not shown), and bro-
melain (data shown in Fig. 2). As a control for specificity an 
irrelevant mAb, directed against the HIV-1 Tat protein, was 
used. Partial proteolysis of GST-Rev with a variety of se-
quence specific proteinases has previously been performed 
and the bands observed could readily be assigned to specific 
amino acids [23]. The positions of the cleavages originating 
from unspecific proteinases were estimated by comparison to 
co-electrophoresed markers. Three different mAbs induced 
contiguous footprints on Rev when using bromelain: (i) 
4G9 protected the N-terminal part of Rev around aa 5-15 
(Fig. 2A, lanes 6 and 11), (ii) 9G2 and 8E7 gave footprints 
at aa positions 65-85 (Fig. 2A, lanes 4 and 9, and Fig. 2B, 
lane 2) and (iii) 1G7 protected cleavages of sequences around 
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Fig. 4. Putative model of the Rev structure based on this report 
and the study by Auer et al. [18]The protection of 1G10 is indicated 
by cross-hatched areas on the model. Cylinders represent oc-helices 
and the C-terminal part of the protein, including the NES, is drawn 
schematically. 
positions 95-105. For mAb 4F2 no effects were seen with the 
proteinases used. 
Interestingly, a discontinuous footprint was obtained with 
mAb 1G10 yielding protection of cleavages both around aa 
10-20 and aa 95-105 (Fig. 2B, compare lanes 1 and 3). The 
footprint was surprising as previous epitope mapping, using a 
binding experiment with overlapping Rev peptides, did not 
find that amino acids in the N-terminal part of Rev were 
involved in 1G10 binding [28]. The epitope mapping results 
obtained by peptide interaction analysis and protein foot-
printing are summarized in Table 1. 
3.2. The conformational epitope is also present in His-tagged 
Rev 
To test whether the discontinuous protection observed with 
mAb 1G10 could be reproduced on a Rev protein lacking the 
GST-tag, we constructed protein expression vectors producing 
Rev protein containing a 6XHis-tag at either the N- or C-
terminus (His-Rev and Rev-His, respectively) and a HMK 
site at the terminus distal to the His-tag (Fig. 1B,C). The 
advantage of using both N- and C-terminally labeled proteins 
in protein footprinting experiments is the ability to distinguish 
primary cleavages (the initial cleavage) from secondary ones 
(cleavages depending on an initial cleavage event). Purified 
His-tagged Rev proteins were incubated with 1G10 and par-
tially cleaved with proteinase K (Fig. 3A,B, lanes 5 and 8). 
Control reactions were performed with Tat mAb 4B4 and Rev 
mAb 9G2 (Fig. 3A,B, lanes 3, 4, 6 and 7). As seen for GST-
Rev, 1G10 also abolished cleavages at positions around aa 
10-20 and aa 95-105 in both types of His-tagged Rev pro-
teins, which lead us to conclude that the effects seen are not 
artefacts due to secondary cleavage events or topological con-
straints imposed on Rev by the purification tags. 9G2 inhib-
ited proteinase K cleavage at an expected position around aa 
80, although in the case of His-Rev the protected bands comi-
grate with the thrombin cleaved marker, indicating a slightly 
more N-terminal position at aa 66 (see legend to Fig. 3 for 
discussion). 
From the footprinting analysis we predict that 1G10 recog-
nizes a conformational epitope in Rev comprised of amino 
acids within positions 10-20 and 95-105, whereas the remain-
ing mAb-binding sites correlate with the epitopes resolved by 
a peptide-binding procedure (Table 1). Thus, in contrast to 
conventional peptide mapping strategies the protein footprint-
ing technique seems to be able to yield additional information 
concerning epitopes consisting of non-linear antigenic deter-
minants. 
3.3. Structural model for Rev 
The discontinuous footprint observed with mAb 1G10 sug-
gests that the termini of Rev are in close proximity. Interest-
ingly, this feature is also favored in the helix-loop-helix mod-
el proposed by Auer et al. [18] (Fig. 4). The protein 
footprinting data cannot resolve whether N- and C-terminal 
residues are in actual molecular contact since sterical hin-
drance to the endoproteinases by the mAb could also account 
for the effects seen. 1G10 recognizes residues more C-terminal 
than 8E7 and 9G2. Since the latter epitope covers amino acids 
in the NES of the Rev protein, it is possible that an interac-
tion of the termini plays an important role in presenting the 
NES to putative cellular partners. More experimental data are 
required to fully verify this model, but it should prove useful 
for experimental design. 
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